Drug Trial Radar · NCT06138743
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
78
Planned (sponsor's estimate)
Start
Mar 4, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1/2a double-blinded, placebo-controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of single and multiple ascending doses of SRP-1003 compared to placebo in male and female participants with type 1 myotonic dystrophy (DM1). Participants who have provided written informed consent and met all protocol eligibility requirements will be randomized to receive single (Part 1) or multiple (Part 2) doses of SRP-1003 or placebo.
Conditions
- Myotonic Dystrophy 1
Interventions
SRP-1003 IV InfusionDrug
SRP-1003 by IV infusion
Placebo IV InfusionDrug
0.9% sodium chloride (NaCl) calculated volume to match active treatment by IV infusion
SRP-1003 SC InjectionDrug
SRP-1003 by SC injection(s)
Placebo SC InjectionDrug
0.9% NaCl calculated volume to match active treatment by SC injection(s)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events Over Time Through End of Study (EOS)Time frame: Single-dose phase (Part 1): Up to Day 90 (EOS); multiple-dose phase (Part 2): Up to Day 180 (EOS)
Locations
35 sites in 11 countries. Site status is shown where the registry gives one.
Nucleus Network Brisbane Clinic
Herston, Australia
Mater Hospital Brisbane
South Brisbane, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Sunshine Coast University Hospital
Birtinya, Queensland, Australia
Royal Brisbane And Women's Hospital
Herston, Queensland, Australia
Alfred Health
Melbourne, Victoria, Australia
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
University Of Calgary
Calgary, Canada
University Of Alberta
Edmonton, Canada
McGill University
Montreal, Canada
University Hospital of Angers
Angers, France
Centre Hospitalier Universitaire De Bordeaux
Bordeaux, France
Centre Hospitalier Universitaire De Lille
Lille, France
CHU de Nice - Hôpital Pasteur 2
Nice, France
Assistance Publique Hôpitaux De Paris
Paris, France
Klinikum der Universität München AöR
Munich, Germany
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.
Ulm, Germany
Fondazione Serena Onlus - Centro Clinico Nemo Brescia
Gussago, Italy
Centro Clinico Nemo (Milan)
Milan, Italy
Azienda Ospedaliera Universitaria Pisana (AOUP)
Pisa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
New Zealand Clinical Research Christchurch
Christchurch, New Zealand
Hospital Universitario Torrecárdenas
Almería, Spain
Hospital Universitari Vall D Hebron
Barcelona, Spain
Hospital Universitario Infanta Sofia
Madrid, Spain
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Siriraj Hospital
Bangkok, Thailand
Lampang Hospital
Lampang, Thailand
Songklanagarind Hospital
Hat Yai, Changwat Songkhla, Thailand
The National Hospital for Neurology and Neurosurgery, NHS Foundation Trust
London, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Southampton General Hospital, NHS Foundation Trust
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.